CNMD CONMED Corp
Electromedical & Electrotherapeutic Apparatus · NYSE · SEC CIK 816956 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.2%
TTM net income YoY-64.5%
TTM EPS YoY-64.5%
Revenue 3-yr CAGR9.6%
Net income 3-yr CAGR—
Margins
Gross margin54.6%
Operating margin7.5%
Net margin3.4%
FCF margin11.0%
EBITDA margin8.7%
Returns
ROE4.7%
ROA2.0%
ROIC (approx.)3.7%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets55.6%
Debt / equity0.81x
Current ratio2.14x
Interest coverage3.30x
Cash quality & payout
Operating cash flow / net income3.63x
Accruals ratio-5.3%
Payout ratio52.6%
Capex / revenue1.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $335.56M | $343.49M | $373.20M | $337.93M | $342.35M | $321.26M | $345.94M | $316.70M |
| Cost of revenue | $146.41M | $146.03M | $154.91M | $171.81M | $154.03M | $143.50M | $147.60M | $137.71M |
| Gross profit | $189.15M | $197.46M | $218.28M | $166.12M | $188.32M | $177.75M | $198.34M | $179.00M |
| R&D expense | $15.59M | $15.50M | $14.90M | $13.90M | $14.14M | $12.95M | $13.18M | $13.56M |
| SG&A expense | $136.42M | $145.55M | $166.76M | $140.34M | $136.02M | $148.85M | $132.67M | $99.73M |
| Operating income | $37.14M | $36.41M | $36.62M | $11.88M | $38.16M | $15.96M | $52.50M | $65.71M |
| Interest expense | $11.13M | $7.88M | $7.37M | $7.61M | $7.82M | $8.29M | $8.86M | $9.25M |
| Pretax income | $26.01M | $31.35M | $29.25M | $4.27M | $29.92M | $7.67M | $43.64M | $56.45M |
| Income tax | $6.21M | $8.28M | $12.51M | $1.41M | $8.50M | $1.64M | $9.89M | $7.47M |
| Net income | $19.80M | $23.07M | $16.74M | $2.86M | $21.42M | $6.04M | $33.76M | $48.98M |
| EBITDA | $41.12M | — | $40.69M | $16.25M | $42.63M | $20.19M | $56.70M | $69.90M |
| EPS (basic) | 0.66 | 0.77 | — | 0.09 | 0.69 | 0.19 | — | 1.59 |
| EPS (diluted) | 0.66 | 0.77 | — | 0.09 | 0.69 | 0.19 | — | 1.57 |
| Dividends declared per share | — | — | -0.00 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 |
| Weighted avg. shares (diluted) | 30.12M | 30.12M | — | 31.05M | 31.05M | 31.15M | — | 31.11M |
| Balance sheet | ||||||||
| Cash & equivalents | $47.97M | $37.33M | $40.82M | $38.93M | $33.94M | $35.48M | $24.46M | $38.47M |
| Receivables | $233.91M | $239.77M | $247.83M | $224.94M | $234.15M | $221.14M | $237.73M | $231.23M |
| Inventory | $362.83M | $360.18M | $355.54M | $364.36M | $362.25M | $354.68M | $346.72M | $342.55M |
| Current assets | $682.04M | $675.66M | $672.86M | $662.16M | $657.78M | $639.00M | $640.01M | $641.00M |
| PP&E, net | $108.77M | $110.14M | $113.33M | $112.04M | $116.86M | $116.06M | $115.79M | $117.42M |
| Goodwill | $796.93M | $796.90M | $807.01M | $806.92M | $806.93M | $805.70M | $805.36M | $806.87M |
| Intangibles | $556.63M | $564.42M | $582.05M | $593.11M | $601.82M | $609.83M | $617.66M | $625.57M |
| Total assets | $2.30B | $2.30B | $2.33B | $2.32B | $2.33B | $2.30B | $2.31B | $2.32B |
| Current liabilities | $458.96M | $455.40M | $315.04M | $314.70M | $294.84M | $283.15M | $278.13M | $282.31M |
| Short-term debt | $180.11M | $177.20M | $712,000 | $746,000 | $714,000 | $714,000 | $715,000 | $717,000 |
| Long-term debt | $635.76M | $657.05M | $834.23M | $853.01M | $881.11M | $891.44M | $905.07M | $940.09M |
| Total debt | $815.87M | $834.25M | $834.94M | $853.75M | $881.83M | $892.16M | $905.78M | $940.81M |
| Total liabilities | $1.24B | $1.26B | $1.29B | $1.31B | $1.33B | $1.32B | $1.34B | $1.38B |
| Shareholders' equity | $1.06B | $1.04B | $1.03B | $1.01B | $1.00B | $977.64M | $962.68M | $932.90M |
| Net debt | $767.89M | $796.92M | $794.12M | $814.82M | $847.89M | $856.67M | $881.32M | $902.34M |
| Cash flow statement | ||||||||
| Operating cash flow | $49.41M | — | $46.34M | $53.69M | $29.13M | $41.53M | $43.34M | $51.20M |
| Capital expenditure | $2.68M | — | $5.11M | $5.19M | $5.73M | $3.78M | $4.04M | $3.42M |
| Free cash flow | $46.73M | — | $41.22M | $48.50M | $23.41M | $37.76M | $39.30M | $47.78M |
| Investing cash flow | -$1.87M | — | -$7.11M | -$5.19M | -$5.73M | -$2.93M | -$4.04M | -$3.42M |
| Financing cash flow | -$36.96M | — | -$37.37M | -$43.52M | -$26.53M | -$28.40M | -$51.07M | -$38.83M |
| Depreciation & amortization | $3.98M | — | $4.07M | $4.38M | $4.47M | $4.24M | $4.20M | $4.20M |
| Stock-based compensation | $5.91M | $5.23M | $4.97M | $4.58M | $4.90M | $13.86M | $6.22M | $6.12M |
| Dividends paid | $0 | — | $6.19M | $6.19M | $6.19M | $6.18M | $6.18M | $6.16M |
| Share buybacks | $6.20M | — | — | $0 | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.